United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team
Source: SeekingAlpha
2026-02-26 11:30:08 ET
Investment Overview
United Therapeutics Corporation ( UTHR ), the Silver Spring, Maryland, headquartered pharma company with a multi-billion dollar pulmonary arterial hypertension ("PAH" a rare, chronic condition characterized by high blood pressure in the lung arteries) drug product franchise, announced its Q4 and full-year 2025 earnings and provided business updates yesterday, February 25th....
Read the full article on Seeking Alpha
For further details see:
United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team
United Therapeutics Corporation
NASDAQ: UTHR
UTHR Trading
10.69% G/L:
$523.46 Last:
406,663 Volume:
$497.75 Open:
UTHR Latest News
March 09, 2026 07:00:00 am
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
March 03, 2026 07:00:00 am
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
March 02, 2026 06:30:00 am
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
February 25, 2026 06:30:00 am
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
UTHR Stock Data
$20,237,032,096
38,621,769
0.2%
368
N/A
Biotechnology & Life Sciences
Healthcare
US
Silver Spring
